BRM521 is a PEDF-derived Short Peptide (PDSP), which is a new drug candidate for osteoarthritis. Its active pharmaceutical ingredient (API) is the same as BRM421, with a different formulation. The final drug product will be an intra-articular injectable, as a first-in-class new drug.
BRM521’s neurotrophic characteristic can induce cartilage proliferation and the differentiation of mesenchymal stem cells, promoting cartilage regeneration, repairing damaged articular cartilage, and relieving symptoms of pain. BRM521’s mechanism of action is shown in multiple animal studies.